

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Dirk Beher et al.	
Serial No.:	To Be Assigned	Case No.: T1615YP
US Nat'l Filing Date:	May 24, 2006	
Int'l Appl'n No.	PCT/GB2004/004985	
Int'l Filing Date:	25 November 2004	
For:	1-ALKYL-3-THIO-SUBSTITUTED INDOLE-2-ALKYNOIC ACIDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS	

MAIL STOP PCT  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT May 24, 2006  
EXPRESS MAIL NO. E1098958535125

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Christine Caffer  
DATE 5-24-06

18/580286

Int'l Appl'n No.: PCT/GB2004/004985  
Case No.: T1615YP  
Page 2

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


APPROVED BY PTO 34 MAY 2006

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A-D on the accompanying PTO 1440 form were cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: May 24, 2006

*(use as many sheets as necessary)*

Sheet

1

of

2

**Application Number**

### To Be Assigned

signed 20/580286

**Filing Date****First Named Inventor**

**Dirk Beher**

## Group Art Unit

### To Be Assigned

Examiner Name

### To Be Assigned

Attorney Docket Number

T1615YP

[illegible][illegible]

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

[illegible]

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.